Table 3.
Mean disease activity at baseline and after 6 months of follow-up for patients treated with infliximab or etanercept
| Disease activity, mean (SD) | ||||
| Infliximab | Etanercept | |||
| INF | CT-P13 | ETN | SB4 | |
| VAS patient, pain (mm) | ||||
| Baseline | 62 (23) | 59 (24) | 59 (24) | 59 (22) |
| 6 months | 32 (26) | 33 (28) | 30 (27) | 28 (25) |
| VAS patient, global (mm) | ||||
| Baseline | 59 (24) | 64 (24) | 57 (22) | 59 (23) |
| 6 months | 33 (26) | 37 (30) | 30 (27) | 30 (24) |
| ASDAS | ||||
| Baseline | 3.37 (1.02) | 3.35 (0.97) | 3.05 (0.90) | 2.98 (0.94) |
| 6 months | 1.95 (1.15) | 2.03 (1.18) | 1.67 (1.01) | 1.65 (0.90) |
| BASDAI | ||||
| Baseline | 5.97 (2.00) | 5.61 (2.03) | 5.36 (2.01) | 5.36 (1.93) |
| 6 months | 3.18 (2.32) | 3.37 (2.61) | 2.95 (2.50) | 2.72 (2.09) |
| BASFI | ||||
| Baseline | 4.38 (2.51) | 4.79 (2.38) | 4.06 (2.36) | 4.09 (2.48) |
| 6 months | 2.37 (2.50) | 3.01 (2.67) | 2.10 (2.22) | 1.74 (1.88) |
| CRP | ||||
| Baseline | 15 (21) | 13 (22) | 11 (18) | 10 (15) |
| 6 months | 6 (11) | 5 (11) | 4 (5) | 3 (4) |
Numbers are means (SD) for patients with available data at the specific time point. The proportion of patients contributing data is shown in online supplementary table S1.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein;CT-P13, infliximab biosimilar; ETN, etanercept originator; INF, infliximab originator; SB4, etanercept biosimilar; VAS, visual analogue scale.